Correction to: The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials

Correction to: Osteoporosis International (2019) 30:1175–1186

https://doi.org/10.1007/s00198-019-04853-7

The original version of this article, published on February 7, 2019, contained a mistake.

The correct information is given below. The original article has been corrected.

Results - Efficacy evaluations - Menatetrenone versus placebo/no additional drug:

“In addition, analysis of four studies [22,24,26,38] (N=356) revealed a significantly greater percent increase in lumbar BMD from baseline for menatetrenone compared with placebo or no additional anti-osteoporotic drug (MD=2.02%, 95% CI 1.05 to 2.99%, P <0.0001) (Fig. 3 and Online Resource 3).”

Fig. 3

Summary of results of the meta-analyses for continuous variables (only summary effect estimate of menatetrenone vs. placebo – LBMD change (%) was changed)

Table 1 . Characteristics of the included RCTs

In the “Outcome” column, the Orimo 1999 study should be “9,12,13” rather than “5,9,12,13”.

Figure 3 Summary of results of the meta-analyses for continuous variables (only summary effect estimate of menatetrenone vs. placebo – LBMD change (%) was changed)

Correction in supplementary material

Online Resource 3 - 3.5 Meta-analysis comparing the percent change in lumbar BMD from baseline between menatetrenone and placebo

Online Resource 5 Sensitivity analyses using the “metaninf” function – 5.1 Vitamin K2 versus placebo/no additional drug for efficacy evaluation – 5.1.5 LBMD(%)